Investigational drugs for the treatment of infections caused by multidrug-resistant Gram-negative bacteria

Expert Opinion on Investigational Drugs

Volumn 27, Issue 4, 2018, Pages 325-338

  Avery, Lindsay M ^a   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

carbapenem resistant Enterobacteriaceae; Drug development; multidrug resistant

Indexed keywords

ANTIBIOTIC AGENT; AVIBACTAM; AZTREONAM; CEFEPIME; CEFIDEROCOL; CEFTAROLINE; DELAFLOXACIN; ERAVACYCLINE; FINAFLOXACIN; IMIPENEM; MEROPENEM; MEROPENEM PLUS VABORBACTAM; MUREPAVADIN; NACUBACTAM; OMADACYCLINE; PLAZOMICIN; RELEBACTAM; UNCLASSIFIED DRUG; VABORBACTAM; VNRX 5133; ZIDEBACTAM; ANTIINFECTIVE AGENT; NEW DRUG;

ACINETOBACTER BAUMANNII; ANTIBIOTIC THERAPY; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; COST BENEFIT ANALYSIS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESEARCH; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFECTION; INFECTION CONTROL; PSEUDOMONAS AERUGINOSA; REVIEW; ANIMAL; DRUG DESIGN; DRUG EFFECTS; DRUG POTENTIATION; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTION; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; ISOLATION AND PURIFICATION; MICROBIOLOGY; MULTIDRUG RESISTANCE; PROCEDURES;

ANIMALS; ANTI-BACTERIAL AGENTS; DRUG DESIGN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; DRUGS, INVESTIGATIONAL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INFECTION CONTROL;

EID: 85045510545     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1080/13543784.2018.1460354     Document Type: Review

References (112)

1. Cerceo E, Deitelzweig SB, Sherman BM, et al. Multidrug-resistant Gram-negative bacterial infections in the hospital setting: overview, implications for clinical practice, and emerging treatment options. Microb Drug Resist. 2016;22:412–431.
2. Falagas ME, Karageorgopoulos DE., Pandrug Resistance (PDR), Extensive Drug Resistance (XDR), and Multidrug Resistance (MDR) among Gram-negative bacilli: need for international harmonization in terminology. Clin Infect Dis. 2008;46:1121–1122.
3. Ruppé É, Woerther P-L, Barbier F., Mechanisms of antimicrobial resistance in Gram-negative bacilli. Ann Intensive Care. 2015;5:61.
4. Lagacé-Wiens P, Walkty A, Karlowsky JA. Ceftazidime–avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections. Core Evid. 2014;9:13–25.
5. Antibiotic resistance threats in the United States. 2013. [Internet]. Atlanta: Centers for Disease Control and Prevention; [cited 2017 Aug2] Available from: https://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf
6. Nathwani D, Raman G, Sulham K, et al. Clinical and economic consequences of hospital-acquired resistant and multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis. Antimicrob Resist Infect Control. 2014;3:1–16.
7. Schmier JK, Hulme Lowe CK, Klenk JA, et al. Economic burden and healthcare resource utilization associated with multi-drug resistant Acinetobacter baumannii: a structured review of the literature. J Pharm Care Heal Syst. 2016;3:1–7.
8. Inchai J, Pothirat C, Bumroongkit C, et al. Prognostic factors associated with mortality of drug-resistant Acinetobacter baumannii ventilator-associated pneumonia. J Intensive Care. 2015;3:1–8.
9. Morales E, Cots F, Sala M, et al. Hospital costs of nosocomial multi-drug resistant Pseudomonas aeruginosa acquisition. BMC Health Serv Res. 2012;12:1–8.
10. Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug-resistant bacterial infections, including tuberculosis. Geneva: World Health Organization. 2017. (WHO/EMP/IAU/2017.12) (License: CC BY-NC-SA 3.0 IGO).
11. Xu L, Sun X, Ma X. Systematic review and meta-analysis of mortality of patients infected with carbapenem-resistant Klebsiella pneumoniae. Ann Clin Microbiol Antimicrob. 2017;16:1–12.
12. Livermore DM, Mushtaq S, Warner M, et al. In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria. J Antimicrob Chemother. 2017;72:1373–1385.
13. Sader HS, Rhomberg PR, Flamm RK, et al. WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamases. J Antimicrob Chemother. 2017;72:1696–1703.
14. Joshi PR, Khande HN, Takalkar SS, et al. WCK 5222: in vitro and in vivo coverage of OXA-carbapenemases expressing-Acinetobacter. Poster session presented at: ASM Microbe; 2016 Jun16–20; Boston, MA.
15. Sader HS, Castanheira M, Huband M, et al. WCK 5222 (cefepime-zidebactam) antimicrobial activity against clinical isolates of Gram-negative bacteria collected worldwide in 2015. Antimicrob Agents Chemother. 2017;61:1–11.
16. Moya B, Barcelo IM, Bhagwat S, et al. Potent β-lactam enhancer activity of zidebactam and WCK 5153 against Acinetobacter baumannii, including carbapenemase-producing clinical isolates. Antimicrob Agents Chemother. 2017;61:1–25.
17. Moya B, Barcelo IM, Bhagwat S, et al. WCK 5107 (zidebactam) and WCK 5153 are novel inhibitors of PBP2 showing potent β-lactam enhancer activity against Pseudomonas aeruginosa, including multidrug-resistant metallo-β-lactamase-producing high-risk clones. Antimicrob Agents Chemother. 2017;61:1–34.
18. WCK 4282 [Internet]. Wockhardt Ltd., Inc. [cited 2017 Nov28]. Available from: http://wockhardtdiscovery.com/wck-4282/
19. Livermore DM, Mushtaq S, Warner M, et al. Activity of OP0595/β-lactam combinations against Gram-negative bacteria with extended-spectrum, AmpC and carbapenem-hydrolysing β-lactamases. J Antimicrob Chemother. 2015;70:3032–3041.
20. Morinaka A, Tsutsumi Y, Yamada M, et al. OP0595, a new diazabicyclooctane: mode of action as a serine β-lactamase inhibitor, antibiotic and β-lactam “enhancer.”. J Antimicrob Chemother. 2015;70:2779–2786.
21. Morinaka A, Tsutsumi Y, Yamada K, et al. In vitro and in vivo activities of OP0595, a new diazabicyclooctane, against CTX-M-15-positive Escherichia coli and KPC-positive Klebsiella pneumoniae. Antimicrob Agents Chemother. 2016;60:3001–3006.
22. Kaku N, Kosai K, Takeda K, et al. Efficacy and pharmacokinetics of the combination of OP0595 and cefepime in a mouse model of pneumonia caused by ESBL-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2017;61:1–8.
23. Crandon JL, Nicolau DP. In vitro activity of cefepime/AAI101 and comparators against cefepime non-susceptible Enterobacteriaceae. Pathogens. 2015;4:620–625.
24. Crandon JL, Nicolau DP. In vivo activities of simulated human doses of cefepime and cefepime-AAI101 against multidrug-resistant Gram-negative Enterobacteriaceae. Antimicrob Agents Chemother. 2015;59:2688–2694.
25. Pipeline [Internet]. Weil am Rhein: Allecra Therapeutics; [cited 2017 Nov28]. Available from: https://allecra.com/pipeline/
26. Allecra announces initiation of a phase 2 clinical trial for its novel antibiotic to treat resistant bacterial infections [Internet]. Weil am Rhein (Germany): Allecra Therapeutics; [cited 2017 Nov28]. Available from: https://allecra.com/2017/09/07/allecra-announces-initiation-of-a-phase-2-clinical-trial-for-its-novel-antibiotic-to-treat-resistant-bacterial-infections/
27. Paul Taylor N. VenatoRx raises $42M to take drug for breaking bacterial resistance to approval [Internet]. FierceBiotech. 2017 [cited 2017 Nov28]. Available from: https://www.fiercebiotech.com/biotech/venatorx-raises-42m-to-take-drug-for-breaking-bacterial-resistance-to-approval
28. Sy SKB, Beaudoin ME, Zhuang L, et al. In vitro pharmacokinetics/pharmacodynamics of the combination of avibactam and aztreonam against MDR organisms. J Antimicrob Chemother. 2016;71:1866–1880.
29. Karlowsky JA, Kazmierczak KM, de Jonge BLM, et al. In vitro activity of aztreonam-avibactam against Enterobacteriaceae and Pseudomonas aeruginosa isolated by clinical laboratories in 40 countries from 2012 to 2015. Antimicrob Agents Chemother. 2017;61:1–21.
30. Biedenbach DJ, Kazmierczak K, Bouchillon SK, et al. In vitro activity of aztreonam-avibactam against a global collection of Gram-negative pathogens from 2012 and 2013. Antimicrob Agents Chemother. 2015;59:4239–4248.
31. Castanheira M, Williams G, Jones RN, et al. Activity of ceftaroline-avibactam tested against contemporary Enterobacteriaceae isolates carrying β-lactamases prevalent in the United States. Microb Drug Resist. 2014;20:436–440.
32. Castanheira M, Sader HS, Farrell DJ, et al. Activity of ceftaroline-avibactam tested against Gram-negative organism populations, including strains expressing one or more beta-lactamases and methicillin-resistant Staphylococcus aureus carrying various Staphylococcal cassette chromosome mec types. Antimicrob Agents Chemother. 2012;56:4779–4785.
33. Riccobene TA, Su SF, Rank D. Single-and multiple-dose study to determine the safety, tolerability, and pharmacokinetics of ceftaroline fosamil in combination with avibactam in healthy subjects. Antimicrob Agents Chemother. 2013;57:1496–1504.
34. Bush K, Page MGP. What we may expect from novel antibacterial agents in the pipeline with respect to resistance and pharmacodynamic principles. J Pharmacokinet Pharmacodyn. 2017;44:113–132.
35. Wagenlehner FME, Wagenlehner CM, Blenk B, et al. Urinary pharmacokinetics and bactericidal activity of finafloxacin (200 and 800 mg) in healthy volunteers receiving a single oral dose. Chemotherapy. 2011;57:97–107.
36. Armaganidis A, Frantzeskaki F, Diakaki C, et al. Pharmacokinetic and efficacy analysis of murepavadin co-administered with standard-of-care in a phase II study in patients with ventilator-associated pneumonia due to suspected or documented P. aeruginosa infection. Poster session presented at: ECCMID; 2017; Vienna, Austria.
37. Leidig M, Schaumann F, Beni L, et al. Pharmacokinetics of murepavadin (POL7080) in a drug-drug interaction study in healthy subjects. Poster session presented at: ECCMID; 2017; Vienna, Austria.
38. Murepavadin (POL7080) [Internet]. Polyphor Ltd. [cited 2017 Nov7]. Available from: https://www.polyphor.com/pol7080/
39. XTORO (finafloxacin otic suspension) [package insert]. Fort Worth (TX): Novartis; 2014. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206307s000lbl.pdf
40. Finafloxacin [Internet]. MerLion Pharmaceuticals. 2009 [cited 2017 Nov8]; Available from: http://www.merlionpharma.com
41. Stubbings W, Leow P, Yong GC, et al. In vitro spectrum of activity of finafloxacin, a novel, pH-activated fluoroquinolone, under standard and acidic conditions. Antimicrob Agents Chemother. 2011;55:4394–4397.
42. Kocsis B, Domokos J, Szabo D. Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacin. Ann Clin Microbiol Antimicrob. 2016;15:1–8.
43. Dalhoff A, Schubert S, Vente A. Pharmacodynamics of finafloxacin, ciprofloxacin, and levofloxacin in serum and urine against TEM- and SHV-type extended-spectrum-beta -lactamase-producing Enterobacteriaceae isolates from patients with urinary tract infections. Antimicrob Agents Chemother. 2017;61:1–10.
44. Falagas ME, Skalidis T, Vardakas KZ, et al. Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals. J Antimicrob Chemother. 2017;72:1704–1708.
45. Hackel MA, Tsuji M, Yamano Y, et al. In vitro activity of the siderophore cephalosporin, cefiderocol, against a recent collection of clinically relevant Gram-negative bacilli from North America and Europe, including carbapenem non-susceptible isolates: the SIDERO-WT-2014 study. Antimicrob Agents Chemother. 2017;61:1–22.
46. Monogue ML, Tsuji M, Yamano Y, et al. Efficacy of humanized exposures of cefiderocol (S-649266) against a diverse population of Gram-negative bacteria in the murine thigh infection model. Antimicrob Agents Chemother. 2017;61:1–10.
47. Shionogi presents positive clinical efficacy trial results and in vitro data on cefiderocol at IDWeek [Internet]. PR Newswire. 2017 [cited 2017 Nov1]. Available from: https://www.prnewswire.com/news-releases/shionogi-presents-positive-clinical-efficacy-trial-results-and-in-vitro-data-on-cefiderocol-at-idweek-2017-300531234.html
48. Livermore DM, Mushtaq BS, Warner AM, et al. In vitro activity of eravacycline against carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii. Antimicrob Agents Chemother. 2016;60:3840–3844.
49. Tygacil (tigecycline) [Internet]. FDA. [cited 2018 Feb22]; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021821s021lbl.pdf
50. Solomkin J, Evans D, Slepavicius A, et al. Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the investigating Gram-negative infections treated with eravacycline (IGNITE 1) trial: a randomized clinical trial. JAMA Surg. 2017;152:224–232.
51. Sutcliffe JA, O ’Brien W, Fyfe C, et al. Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens. Antimicrob Agents Chemother. 2013;57:5548–5558.
52. Solomkin JS, Ramesh MK, Cesnauskas G, et al. Phase 2, randomized, double-blind study of the efficacy and safety of two dose regimens of eravacycline versus ertapenem for adult community-acquired complicated intra-abdominal infections. Antimicrob Agents Chemother. 2014;58:1847–1854.
53. Zhanel GG, Cheung D, Adam H, et al. Review of eravacycline, a novel fluorocycline antibacterial agent. Drugs. 2016;76:567–588.
54. IGNITE2: Eravacycline inferior to levofloxacin, but IV formulation shows promise [Internet]. Healio; [cited 2017 Nov20]. Available from: https://www.healio.com/infectious-disease/antimicrobials/news/online/
55. Tetraphase announces top-line results from IGNITE3 phase 3 clinical trial of eravacycline in complicated Urinary Tract Infections (cUTI) [Internet]. Tetraphase. [cited 2018 Feb22]. Available from: http://ir.tphase.com/news-releases/news-release-details/tetraphase-announces-top-line-results-ignite3-phase-3-clinical
56. Lob SH, Hackel MA, Kazmierczak KM, et al. In vitro activity of imipenem-relebactam against Gram-negative bacilli isolated from patients with lower respiratory tract infections in the United States in 2015: results from the SMART global surveillance program. Antimicrob Agents Chemother. 2017;61:1–9.
57. Livermore DM, Warner M, Mushtaq S. Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa. J Antimicrob Chemother. 2013;68:2286–2290.
58. Haidar G, Clancy CJ, Chen L, et al. Identifying spectra of activity and therapeutic niches for ceftazidime-avibactam and imipenem-relebactam against carbapenem-resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2017;61:1–17.
59. Snydman DR, Jacobus NV, McDermott LA. In vitro evaluation of the activity of imipenem-relebactam against 451 recent clinical isolates of Bacteroides group and related species. Antimicrob Agents Chemother. 2016;60:6393–6397.
60. Lucasti C, Vasile L, Sandesc D, et al. Phase 2, dose-ranging study of relebactam with imipenem-cilastatin in subjects with complicated intra-abdominal infection. Antimicrob Agents Chemother. 2016;60:6234–6243.
61. Sims M, Mariyanovski V, McLeroth P, et al. Prospective, randomized, double-blind, phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections. J Antimicrob Chemother. 2017;72:2616–2626.
62. Draper MP, Weir S, Macone A, et al. Mechanism of action of the novel aminomethylcycline antibiotic omadacycline. Antimicrob Agents Chemother. 2014;58:1279–1283.
63. Honeyman L, Ismail M, Nelson ML, et al. Structure-activity relationship of the aminomethylcyclines and the discovery of omadacycline. Antimicrob Agents Chemother. 2015;59:7044–7053.
64. Pfaller M, Huband MD, Rhomberg PR, et al. Surveillance of omadacycline activity against clinical isolates from a global collection (North America, Europe, Latin America, Asia-Western Pacific), 2010–2011. Antimicrob Agents Chemother. 2017;61:1–7.
65. Macone AB, Caruso BK, Leahy RG, et al. In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline. Antimicrob Agents Chemother. 2014;58:1127–1135.
66. Paratek announces phase 3 study of oral-only dosing of omadacycline met all primary and secondary FDA and EMA efficacy endpoints in acute bacterial skin infections [Internet]. GlobeNewswire, Inc. 2017 [cited 2017 Nov1]. Available from: https://globenewswire.com/news-release/
67. Omadacycline activity vs. CDC serious antibiotic resistance threats [Internet]. Paratek, Pharmaceuticals, Inc. [Internet]. 2016 [cited 2017 Nov20]. Available from: http://paratekpharma.com/media/1332/omadacycline-coverage-for-cdc-pathogen-threats-dk-11-23-16.pdf
68. Plazomicin [Internet]. Achaogen, Inc. 2017 [cited 2017 Nov]. Available from: http://www.achaogen.com/plazomicin/
69. Zhanel GG, Lawson CD, Zelenitsky S, et al. Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin. Expert Rev Anti Infect Ther. 2012;10:459–473.
70. Livermore DM, Mushtaq S, Warner M, et al. Activity of aminoglycosides, including ACHN-490, against carbapenem resistant Enterobacteriaceae isolates. J Antimicrob Chemother. 2011;66:48–53.
71. Endimiani A, Hujer KM, Hujer AM, et al. ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates. Antimicrob Agents Chemother. 2009;53:4504–4507.
72. Walkty A, Adam H, Baxter M, et al. In vitro activity of plazomicin against 5,015 Gram-negative and Gram-positive clinical isolates obtained from patients in Canadian hospitals as part of the CANWARD study, 2011–2012. Antimicrob Agents Chemother. 2014;58:2554–2563.
73. Landman D, Kelly P, Backer M, et al. Antimicrobial activity of a novel aminoglycoside, ACHN-490, against Acinetobacter baumannii and Pseudomonas aeruginosa from New York City. J Antimicrob Chemother. 2011;66:332–334.
74. Karaiskos I, Giamarellou H. Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches. Expert Opin Pharmacother. 2014;15:1–20.
75. Connolly LE, Jubb AM, Keeffe BO, et al. Plazomicin is associated with improved survival and safety compared with colistin in the treatment of serious infections due to carbapenem-resistant Enterobacteriaceae: results of the CARE study. Poster session presented at: ECCMID; 2017; Vienna, Austria.
76. McCurdy S, Lawrence L, Quintas M, et al. In vitro activity of delafloxacin and microbiological response against fluoroquinolone susceptible and non-susceptible S. Aureus Isolates Two Phase 3 Studies Acute Bacterial Skin Skin Structure Infections (ABSSSI). Antimicrob Agents Chemother. 2017;61:1–16.
77. Almer LS, Hoffrage JB, Keller EL, et al. In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against Gram-positive and Gram-negative organisms. Antimicrob Agents Chemother. 2004;48:2771–2777.
78. Lepak AJ, Andes DR. In vivo pharmacodynamic target assessment of delafloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumoniae in a murine lung infection model. Antimicrob Agents Chemother. 2016;60:4764–4769.
79. Candel FJ, Peñuelas M. Delafloxacin: design, development and potential place in therapy. Drug Des Devel Ther. 2017;11:881–891.
80. Baxdela [package insert]. Lincolnshire (IL): Melinta Therapeutics, Inc.; 2017. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208610s000,208611s000lbl.pdf
81. Castanheira M, Rhomberg PR, Flamm RK, et al. Effect of the beta-lactamase inhibitor vaborbactam combined with meropenem against serine carbapenemase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2016;60:5454–5458.
82. Vabomere [package insert]. Parsippany (NJ): The Medicines Company; 2017. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209776lbl.pdf
83. Lapuebla A, Abdallah M, Olafisoye O, et al. Activity of meropenem combined with RPX7009, a novel beta-lactamase inhibitor, against Gram-negative clinical isolates in New York City. Antimicrob Agents Chemother. 2015;59:4856–4860.
84. Carbavance® (meropenem-vaborbactam)- TANGO-1 phase III trial results [Internet]. The Medicines Company. 2016 [cited 2017 Nov1]. Available from: http://phx.corporate-ir.net/
85. TM (meropenem and vaborbactam) at IDWeek 2017 [Internet]. The Medicines Company. [cited 2017 Nov20]; Available from: http://www.themedicinescompany.com/investors/news/medicines-company-present-new-data-tango-ii-study-vabomereTM-meropenem-and-vaborbactam
86. Antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline, including tuberculosis [Internet]. Geneva: the World Health Organization (WHO). 2017 [cited 2018 Mar7]. Available from: http://www.who.int/medicines/areas/rational_use/antibacterial_agents_clinical_development/en/
87. Sun D, Rubio-Aparicio D, Nelson K, et al. Meropenem-vaborbactam resistance selection, resistance prevention, and molecular mechanisms in mutants of KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2017;61:1–14.
88. Tomaras AP, Crandon JL, McPherson CJ, et al. Adaptation-based resistance to siderophore-conjugated antibacterial agents by Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2013;57:4197–4207.
89. Adler A, Friedman ND, Marchaim D. Multidrug-resistant Gram-negative bacilli: infection control implications. Infect Dis Clin North Am. 2016;30:967–997.
90. Friedman ND, Carmeli Y, Walton AL, et al. Carbapenem-resistant Enterobacteriaceae: a strategic roadmap for infection control. Infect Control Hosp Epidemiol. 2017;38:580–594.
91. Richter SS, Marchaim D. Screening for carbapenem-resistant Enterobacteriaceae: who, when, and how? Virulence. 2017;8:417–426.
92. Årdal C, Outterson K, Hoffman SJ, et al. International cooperation to improve access to and sustain effectiveness of antimicrobials. Lancet. 2016;387:296–307.
93. Davido B, Fellous L, Lawrence C, et al. Ceftazidime-avibactam and aztreonam an interesting strategy to overcome β-lactam resistance conferred by metallo-β-lactamases in Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2017;61:1–3.
94. Monogue ML, Abbo L, Rosa R, et al. In vitro discordance with in vivo activity: humanized exposures of ceftazidime-avibactam, aztreonam, and tigecycline alone and in combination against New Delhi metallo-beta-lactamase- producing Klebsiella pneumoniae in a murine lung infection model. Antimicrob Agents Chemother. 2017;61:1–6.
95. Barlam TF, Cosgrove SE, Abbo LM, et al. Implementing an antibiotic stewardship program: guidelines by the infectious diseases society of America and the society for healthcare epidemiology of America. Clin Infect Dis. 2016;62:1197–1202.
96. Crandon JL, Nicolau DP. Human simulated studies of aztreonam and aztreonam-avibactam to evaluate activity against challenging Gram-negative organisms, including metallo-β-lactamase producers. Antimicrob Agents Chemother. 2013;57:3299–3306.
97. Macgowan A, Tomaselli S, Noel A, et al. The pharmacodynamics of avibactam in combination with ceftaroline or ceftazidime against beta-lactamase-producing Enterobacteriaceae studied in an in vitro model of infection. J Antimicrob Chemother. 2017;72:762–769.
98. Wach A, Dembowsky K, Dale GE. Pharmacokinetics and safety of intravenous murepavadin infusion in healthy adult subjects administered as single and multiple ascending doses. Antimicrob. Agents Chemother. 2018;62:1–25.
99. Mouton JW, Melchers MJ, Teague J, et al. Pharmacokinetics and pharmacodynamics of murepavadin in neutropenic lung infection models. Presented at: ECCMID; 2017; Vienna, Austria.
100. Patel H, Andresen A, Vente A, et al. Human pharmacokinetics and safety profile of finafloxacin, a new fluoroquinolone antibiotic, in healthy volunteers. Antimicrob Agents Chemother. 2011;55:4386–4393.
101. Weiss WJ, Pulse M, Renick P, et al. Pharmacokinetics/pharmacodynamics of finafloxacin in the murine thigh infection model with S. aureus and E. coli [Internet]. Merlion Pharmaceuticals. [cited 2018 Mar7]. Available from: http://merlionpharma.com/sites/default/files/ICAAC2010PostersAll.pdf
102. Katsube T, Echols R, Arjona Ferreira JC, et al. Cefiderocol, a siderophore cephalosporin for Gram-negative bacterial infections: pharmacokinetics and safety in subjects with renal impairment. J Clin Pharmacol. 2017;57:584–591.
103. Ghazi IM, Monogue ML, Tsuji M, et al. Pharmacodynamics of cefiderocol, a novel siderophore cephalosporin, in a Pseudomonas aeruginosa neutropenic murine thigh model. Int J Antimicrob Agents. 2018;51:206–212.
104. Connors KP, Housman ST, Pope JS, et al. Phase I, open-label, safety and pharmacokinetic study to assess bronchopulmonary disposition of intravenous eravacycline in healthy men and women. Antimicrob Agents Chemother. 2014;58:2113–2118.
105. Thabit AK, Monogue ML, Newman JV, et al. Assessment of in vivo efficacy of eravacycline against Enterobacteriaceae exhibiting various resistance mechanisms: a dose-ranging study and PK/PD analysis. Int. J. Antimicrob. Agents. 2018 [cited 2018 Mar 1]; [19 p.]. DOI: 10.1016/j.ijantimicag.2018.01.001
106. Rizk ML, Rhee EG, Jumes PA, et al. Intrapulmonary pharmacokinetics of relebactam, a novel β-lactamase inhibitor, dosed in combination with imipenem/cilastatin in healthy subjects. Antimicrob. Agents Chemother. 2018;62:1–29.
107. Mavridou E, Melchers RJB, van Mil ACHAM, et al. Pharmacodynamics of imipenem in combination with β-lactamase inhibitor MK7655 in a murine thigh model. Antimicrob Agents Chemother. 2015;59:790–795.
108. Gotfried MH, Horn K, Garrity-Ryan L, et al. Comparison of omadacycline and tigecycline pharmacokinetics in the plasma, epithelial lining fluid, and alveolar cells of healthy adult subjects. Antimicrob Agents Chemother. 2017;61:1–19.
109. Tzanis E, Manley A, Villano S, et al. Effect of food on the bioavailability of omadacycline in healthy participants. J Clin Pharmacol. 2017;57:321–327.
110. Villano S, Steenbergen J, Loh E. Omadacycline: development of a novel aminomethylcycline antibiotic for treating drug-resistant bacterial infections. Future Microbiol. 2016;11:1421–1434.
111. Cass RT, Brooks CD, Havrilla NA, et al. Pharmacokinetics and safety of single and multiple doses of ACHN-490 injection administered intravenously in healthy subjects. Antimicrob Agents Chemother. 2011;55:5874–5880.
112. Seroogy J, Choi T, Gall J, et al. Pharmacokinetics (PK) of plazomicin in healthy adults. Poster session presented at: ASM; 2017; New Orleans, LA.